中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 41 Issue 2
Feb.  2025
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(2): 277-283

Impact of hepatocellular carcinoma on the prognosis of patients with liver cirrhosis undergoing emergency endoscopic therapy due to esophagogastric variceal bleeding

DOI: 10.12449/JCH250213

  • Department of Gastroenterology，Renmin Hospital of Wuhan University，Wuhan 430060，China

Research funding:

Scientific Research Project of Hubei Provincial Health Commission (WJ2023M078)

More Information
  • Corresponding author: YU Baoping， Yu_Baoping@163.com （ORCID： 0009-0005-0087-5573）
  • Received Date: 2024-07-09
  • Accepted Date: 2024-09-03
  • Published Date: 2025-02-25
    Abstract
  •   Objective  To investigate the impact of hepatocellular carcinoma （HCC） on the prognosis of patients with liver cirrhosis undergoing emergency endoscopic therapy for esophagogastric variceal bleeding， as well as independent influencing factors for the prognosis of liver cirrhosis patients without HCC after emergency endoscopic therapy for esophagogastric variceal bleeding.  Methods  A total of 117 liver cirrhosis patients without HCC and 119 liver cirrhosis patients with HCC who underwent emergency endoscopic therapy for esophagogastric variceal bleeding in Renmin Hospital of Wuhan University from January 2017 to July 2023 were enrolled. Basic information including age and sex was collected from all patients， as well as the presence or absence of chronic diseases such as hypertension， diabetes， and coronary heart disease， the time of emergency endoscopy after admission， and liver function parameters including international normalized ratio， albumin， creatinine， sodium， total bilirubin， alanine aminotransferase， and aspartate aminotransferase （AST）. The independent-samples t test was used for comparison of normally distributed continuous variables between two groups， and the Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous variables between two groups； the chi-square test was used for comparison of categorical variables between groups. The covariance analysis and the multivariate logistic regression analysis were used for comparison of outcome variables after control of baseline variables， and the Kaplan-Meier survival curve was plotted for each group. The univariate and multivariate Cox regression analyses were performed for survival time in the non-HCC group to investigate the independent influencing factors for survival time， and then the Kaplan-Meier curve analysis and the log-rank test were performed to validate such independent influencing factors and analyze the independent influencing factors for secondary outcomes.  Results  Compared with the non-HCC group， the HCC group had significantly higher red blood cell transfusion units （6.00［2.00～9.00］ vs 4.00［1.75～7.00］， Z=-2.050， P=0.040， F=4.869， adjusted P=0.028）， a significantly shorter survival time （29.77±16.01 days vs 38.07±11.43 days， t=4.574， P<0.001， F=17.294， adjusted P<0.001）， and a significantly higher 5-day rebleeding rate （22.69% vs 6.84%， χ2=11.736， P<0.001， adjusted P=0.021）. The Kaplan-Meier curve analysis showed that the risk of 42-day mortality in the HCC group was 3.897 （95% confidence interval ［CI］： 2.338 ‍— 6.495， P<0.001） times that in the non-HCC group. The multivariate Cox regression analysis of the non-HCC group showed that the total length of hospital stay （hazard ratio ［HR］=0.793， 95%CI： 0.644 ‍— ‍0.976， P=0.029） was an independent protective factor for 42-day survival. The Kaplan-Meier curve analysis showed that a length of hospital stay of >9 days was beneficial for the prognosis of patients （HR=4.302， 95%CI： 1.439 — 12.870， P=0.037）. Blood sodium level （odds ratio ［OR］=0.523， 95%CI： 0.289 ‍— ‍0.945， P=0.032） and MELD-Na score （OR=0.495， 95%CI： 0.257 ‍— ‍0.954， P=0.036） were independent protective factors against 5-day rebleeding， while AST level was an independent risk factor for 5-day rebleeding （OR=1.023， 95%CI： 1.002 ‍— ‍1.043， P=0.028） and in-hospital death （OR=1.036， 95%CI： 1.001‍— ‍1.073， P=0.045）.  Conclusion  Liver cirrhosis patients with variceal bleeding and HCC tend to have a worse prognosis， and for the non-HCC group， in-hospital mortality rate increases with the increase in AST level. The total length of hospital stay is an independent protective factor for survival time in the non-HCC group， and it is recommended to appropriately prolong the length of hospital stay for such patients.

     

    • FullText(HTML)
    • References(32)
  • [1]
    HUANG DQ, TERRAULT NA, TACKE F, et al. Global epidemiology of cirrhosis—Aetiology, trends and predictions[J]. Nat Rev Gastroenterol Hepatol, 2023, 20: 388- 398. DOI: 10.1038/s41575-023-00759-2.
    [2]
    DUAH A, DUAH F, AMPOFO-BOOBI D, et al. Acute kidney injury in patients with liver cirrhosis: Prevalence, predictors, and in-hospital mortality at a district hospital in Ghana[J]. Biomed Res Int, 2022, 2022: 4589767. DOI: 10.1155/2022/4589767.
    [3]
    ALLAIRE M, MANFREDI S, LEROSEY L, et al. Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey[J]. Clin Res Hepatol Gastroenterol, 2023, 47( 2): ‍ 102059. DOI: ‍10.1016/j.clinre.2022.102059.
    [4]
    HUANG DQ, TAN DJH, NG CH, et al. Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: Systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2023, 21( 5): ‍ 1169- 1177. ‍ DOI: 10.1016/j.cgh.2022.06.032.
    [5]
    THABUT D, KUDO M. Treatment of portal hypertension in patients with HCC in the era of Baveno VII[J]. J Hepatol, 2023, 78( 3): ‍ 658- 662. ‍ DOI: ‍10.1016/j.jhep.2022.11.019.
    [6]
    LIM J, KIM HI, KIM E, et al. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: A matched nested case-control study[J]. BMC Cancer, 2021, 21( 1): ‍ 11. DOI: ‍10.1186/s12885-020-07708-1.
    [7]
    WU CWK, WONG GLH, WONG VWS, et al. Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages[J]. J Gastroenterol Hepatol, 2023, 38( 8): 1381- 1388. DOI: 10.1111/jgh.16218.
    [8]
    YAO LQ, CHEN ZL, FENG ZH, et al. Clinical features of recurrence after hepatic resection for early-stage hepatocellular carcinoma and long-term survival outcomes of patients with recurrence: A multi-institutional analysis[J]. Ann Surg Oncol, 2022. DOI: 10.1245/s10434-022-11454-y.
    [9]
    AKATEH C, BLACK SM, CONTEH L, et al. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma[J]. World J Gastroenterol, 2019, 25( 28): 3704- 3721. DOI: 10.3748/wjg.v25.i28.3704.
    [10]
    GRALNEK IM, CAMUS DUBOC M, GARCIA-PAGAN JC, et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European society of gastrointestinal endoscopy(ESGE) guideline[J]. Endoscopy, 2022, 54( 11): ‍ 1094- 1120. ‍ DOI: ‍10.1055/a-1939-4887.
    [11]
    LIU KY, ZHANG R, SHI CY, et al. Risk factors for emergency endoscopic variceal ligation treatment failure of acute variceal bleeding[J]. Scand J Gastroenterol, 2022, 57( 12): 1509- 1516. DOI: 10.1080/00365521.2022.2094719.
    [12]
    GAO ZJ, ZHAO JR, LIU XF, et al. Portal vein thrombosis associated with high 14-day and 6-week rebleeding in patients after oesophageal variceal band ligation: A retrospective, multicentre, nested case-control study[J]. Hepatol Int, 2021, 15( 5): 1183- 1195. DOI: 10.1007/s12072-021-10224-4.
    [13]
    STANLEY AJ, LAINE L. Management of acute upper gastrointestinal bleeding[J]. BMJ, 2019, 364: 1536. DOI: 10.1136/bmj.1536.
    [14]
    National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
    [15]
    SCHUPPAN D, AFDHAL NH. Liver cirrhosis[J]. Lancet, 2008, 371( 9615): 838- 851. DOI: 10.1016/S0140-6736(08)60383-9.
    [16]
    GUINAZU C, FERNÁNDEZ MUÑOZ A, MALDONADO MD, et al. Assessing the predictive factors for bleeding in esophageal variceal disease: A systematic review[J]. Cureus, 2023, 15( 11): e48954. DOI: 10.7759/cureus.48954.
    [17]
    TAPPER EB, FRIDERICI J, BORMAN ZA, et al. A multicenter evaluation of adherence to 4 major elements of the baveno guidelines and outcomes for patients with acute variceal hemorrhage[J]. J Clin Gastroenterol, 2018, 52( 2): 172- 177. DOI: 10.1097/MCG.0000000000000820.
    [18]
    ZUCKERMAN MJ, ELHANAFI S, MENDOZA LADD A. Endoscopic treatment of esophageal varices[J]. Clin Liver Dis, 2022, 26( 1): 21- 37. DOI: 10.1016/j.cld.2021.08.003.
    [19]
    LEE YR, PARK SY, TAK WY. Treatment outcomes and prognostic factors of acute variceal bleeding in patients with hepatocellular carcinoma[J]. Gut Liver, 2020, 14( 4): 500- 508. DOI: 10.5009/gnl19155.
    [20]
    REDDY KR, MCLERRAN D, MARSH T, et al. Incidence and risk factors for hepatocellular carcinoma in cirrhosis: The multicenter hepatocellular carcinoma early detection strategy(HEDS) study[J]. Gastroenterology, 2023, 165( 4): 1053- 1063. e 6. DOI: 10.1053/j.gastro.2023.06.027.
    [21]
    CARR BI, BAG HG, INCE V, et al. A combination of blood lymphocytes and AST levels distinguishes patients with small hepatocellular carcinomas ‍from ‍non-cancer patients[J]. ‍ J ‍Gastrointest Cancer, ‍ 2021, ‍ 52( 4): ‍ 1211- 1216. DOI: 10.1007/s12029-021-00740-9.
    [22]
    ZHANG WZ, XU XS, CAI LP, et al. Dysbiosis of the gut microbiome in elderly patients with hepatocellular carcinoma[J]. Sci Rep, 2023, 13: 7797. DOI: 10.1038/s41598-023-34765-w.
    [23]
    SRINIVASA S, LEE WG, ALDAMEH A, et al. Spontaneous hepatic haemorrhage: A review of pathogenesis, aetiology and treatment[J]. HPB(Oxford), 2015, ‍ 17( 10): 872- 880. DOI: 10.1111/hpb.12474.
    [24]
    ZHANG M, DING QH, BIAN CB, et al. Progress on the molecular mechanism of portal vein tumor thrombosis formation in hepatocellular carcinoma[J]. Exp Cell Res, 2023, 426( 1): ‍ 113563. DOI: ‍10.1016/j.yexcr.2023.113563.
    [25]
    ZANETTO A, CAMPELLO E, SENZOLO M, et al. The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive ‍review[J]. ‍ Hepatology, ‍ 2024, ‍ 79( 2): ‍ 460- 481. ‍ DOI: ‍10.1097/HEP.0000000000000349.
    [26]
    ZANETTO A, CAMPELLO E, BURRA P, et al. Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein ‍thrombosis[J]. ‍ Liver ‍Int, ‍ 2023, ‍ 43( 1): ‍ 155- 159. ‍ DOI: ‍10.1111/liv.15435.
    [27]
    BALCAR L, MREKVA A, SCHEINER B, et al. Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion[J]. Cancer Imag, 2024, 24( 1): 9. DOI: 10.1186/s40644-024-00657-z.
    [28]
    ALLAIRE M, RUDLER M, THABUT D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses[J]. Liver Int, 2021, 41( 8): 1734- 1743. DOI: 10.1111/liv.14977.
    [29]
    CHEN CW, KUO CJ, LEE CW, et al. Albumin-bilirubin grade as a novel predictor of the development and short-term survival of post-banding ulcer bleeding following endoscopic variceal ligation in cirrhotic patients[J]. Medicina(Kaunas), 2022, 58( 12): 1836. DOI: 10.3390/medicina58121836.
    [30]
    MAHMUD N, FRICKER Z, HUBBARD RA, et al. Risk prediction models for post-operative mortality in patients with cirrhosis[J]. Hepatology, 2021, 73( 1): 204- 218. DOI: 10.1002/hep.31558.
    [31]
    LIU YB, CHEN MK. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions[J]. World J Gastroenterol, 2022, 28( 41): 5910- 5930. DOI: 10.3748/wjg.v28.i41.5910.
    [32]
    LIU Y, ZHENG JX, HAO JL, et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019[J]. Cancer Med, 2022, 11( 5): 1310- 1323. DOI: 10.1002/cam4.4551.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1809) PDF downloads(10) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[3590]YesterdayPV[6562]TodayIP[1063]TodayPV[1470]Online[197]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return